Diseases / Glaucoma
Glaucoma
DiseaseGlaucoma is a group of eye diseases that damage the optic nerve and can cause progressive vision loss if untreated. It is often asymptomatic in early stages and can lead to irreversible blindness. Early detection and intraocular pressure-lowering treatment are central to management.
- Trials
- 1350
- Recruiting
- 120
- Completed
- 792
- With results
- 215
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | — | — | 1 | 7 | — | — | — | — | — | 9 |
| Phase 1 | 1 | 1 | — | 1 | 26 | 2 | 2 | — | 4 | — | 37 |
| Phase 1/2 | 4 | 1 | — | 2 | 16 | 2 | 1 | — | 6 | — | 32 |
| Phase 2 | 3 | — | — | 3 | 70 | 2 | 2 | — | 4 | — | 84 |
| Phase 2/3 | — | — | — | — | 10 | — | — | — | 1 | — | 11 |
| Phase 3 | 6 | 1 | 1 | — | 82 | 10 | 2 | 2 | 14 | — | 118 |
| Phase 4 | 8 | 3 | — | 2 | 125 | 12 | 7 | — | 25 | — | 182 |
| Not applicable | 61 | 19 | 4 | 8 | 254 | 28 | 16 | 2 | 112 | — | 504 |
| Unknown | 36 | 10 | 6 | 12 | 202 | 19 | 8 | — | 79 | 1 | 373 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | 9 | 37 | 32 | 84 | 11 | 118 | 182 | 504 | 373 | 1350 |
| Ocular Hypertension | — | 15 | 18 | 51 | 1 | 65 | 63 | 49 | 56 | 318 |
| Glaucoma, Open-Angle | — | 6 | 12 | 34 | 3 | 38 | 48 | 89 | 59 | 289 |
| Cataract | 1 | — | 3 | 1 | — | 7 | 5 | 38 | 21 | 76 |
| Eye Diseases | 1 | 4 | 1 | 3 | — | 1 | 8 | 20 | 10 | 48 |
| Macular Degeneration | — | — | — | — | 1 | — | — | 21 | 23 | 45 |
| Diabetic Retinopathy | — | — | — | 1 | — | — | — | 22 | 17 | 40 |
| Hypertension | — | — | — | 6 | — | 9 | 4 | 5 | 3 | 27 |
| Low Tension Glaucoma | — | — | 1 | 3 | — | — | 4 | 7 | 12 | 27 |
| Glaucoma, Angle-Closure | — | — | — | 1 | 1 | 2 | — | 12 | 10 | 26 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Alcon Research | 77 | 23 |
| 2 | Wills Eye | 37 | 3 |
| 3 | Allergan | 33 | 12 |
| 4 | Glaukos Corporation | 22 | 4 |
| 5 | Medical University of Vienna | 17 | 1 |
| 6 | Stanford University | 16 | 0 |
| 7 | University of Zurich | 16 | 0 |
| 8 | Duke University | 14 | 0 |
| 9 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 14 | 4 |
| 10 | Sensimed AG | 14 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Latanoprost | 92 |
| 2 | Timolol | 75 |
| 3 | Travoprost | 63 |
| 4 | Ophthalmic Solutions | 52 |
| 5 | Trabeculectomy | 44 |
| 6 | Bimatoprost | 42 |
| 7 | Brimonidine Tartrate | 35 |
| 8 | brinzolamide | 35 |
| 9 | dorzolamide | 26 |
| 10 | Mitomycin | 24 |
Evidence
- Results reported
- 27.1%215 of 792 completed
- Published
- 15%119 of 792 completed
- Primary endpoint met
- 28%35 of 125 analyses
- Median months to report
- 14
Documents disclosed
Trial profile
- Median enrollment
- 70
- Median duration
- 21.3months
- Countries
- 80
- Study sites
- 2434
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 56
- Phase 1
- 24
- Phase 1/2
- 65
- Phase 2
- 83
- Phase 2/3
- 40
- Phase 3
- 141
- Phase 4
- 56
- Not applicable
- 60
- Unknown
- 100
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Philadelphia | United States | 54 |
| 2 | New York | United States | 42 |
| 3 | Guangzhou | China | 32 |
| 4 | San Antonio | United States | 30 |
| 5 | Toronto | Canada | 29 |
| 6 | London | United Kingdom | 28 |
| 7 | Durham | United States | 27 |
| 8 | Houston | United States | 27 |
| 9 | Madrid | Spain | 26 |
| 10 | Newport Beach | United States | 26 |
Terminations
- Terminated
- 75
- Withdrawn
- 38
- Suspended
- 4
- Stopped for recruitment
- 1.9%26 of 1350 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05581498 Withdrawn | Withdrawn | Lack of funding | 2028-12-31 |
| NCT06709300 Withdrawn | Withdrawn | Executive decision by the company not to execute the study | 2026-07-31 |
| NCT06230393 Terminated | Terminated | Sponsor decision to close this extension study due to reduction in sample size. | 2025-12-04 |
| NCT04500574 Terminated | Terminated | Low recruitment | 2025-10-10 |
| NCT07071129 Terminated | Terminated | Due to Covid pandemic | 2025-09-07 |
| NCT06321562 Terminated | Terminated | The study was terminated early due to the difficulties to enrol participant | 2025-06-26 |
| NCT05690152 Terminated | Terminated | Study software was discontinued prior to completion of the study. 8 total subjects had been recruited at that time, but none completed the duration of the study period. | 2025-03-10 |
| NCT06190028 Terminated | Terminated | The investigation was prematurely interrupted with 65 patients enrolled due to difficulties in recruiting patients. However the results observed in the interim analysis demonstrate the performance of the investigational device. | 2025-03-10 |
| NCT03798145 Withdrawn | Withdrawn | Investigator left institution | 2024-12-31 |
| NCT05273385 Terminated | Terminated | A similar study has been published by other groups and this study is no longer needed. | 2024-12-10 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: